Healius reaffirms AUD 39.7 million EBIT outlook: RBC rates Healius stock Hold

Published on 10/25/2026 at 00:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Healius reaffirmed FY2027 EBIT guidance at AUD 39.7 million on October 22, 2026. An AUD 0.46 target gives Healius stock a valuation reference.

Guidance and operating progress

Healius reaffirmed its FY2027 EBIT guidance at AUD 39.7 million on October 22, 2026.
FY2026 revenue rose 2.1 percent to AUD 1.37 billion.
Healius had a market capitalization of AUD 315.9 million as of October 23, 2026.

Healius, AU0000033359, Illustration mit AI erstellt.

Healius (ISIN AU0000033359) reaffirmed its FY2027 EBIT guidance at AUD 39.7 million at its annual meeting on October 22, 2026. Quartr reported that first-quarter FY2027 pathology revenue rose 1.6 percent, although episodes fell 4.9 percent.

AGM keeps earnings path intact

The operating mix is doing more work. Average fees increased 6 percent in the first quarter, while like-for-like volumes rose 1.1 percent and total costs fell 0.5 percent, according to Quartr.

The chronology shows the strategic reset. On September 25, 2026, Healius agreed to sell Agilex Biolabs for AUD 160 million, with expected net cash proceeds of AUD 155 million in the second half of FY2027, as Stocklight reported. On August 18, 2026, FY2026 underlying revenue rose 2.1 percent to AUD 1.37 billion and underlying EBIT reached AUD 30.2 million, according to Yahoo Finance. On October 22, 2026, the AGM reaffirmed the FY2027 guidance.

What does the cost plan mean?

Healius is trying to turn efficiency into cash generation. Annualized corporate cost savings reached AUD 24.4 million in FY2026, while underlying EBITDA rose 8.1 percent to AUD 258.6 million. The company also expects positive cash flow in FY2027, although Fair Work Commission costs are a material offset.

The main counter-factor is volume pressure. Stockhead reported that September-quarter pathology revenue rose 1.6 percent despite a 4.9 percent episode decline after two hospital contracts were lost. The same report said like-for-like episode volumes increased 1.1 percent and underlying earnings were expected to rise 31 percent in FY2027.

Valuation and reporting dates

RBC Capital maintained a Hold rating and an AUD 0.46 price target on October 22, 2026, according to Markets Insider. The next scheduled earnings date shown by TradingView is February 24, 2027.

Healius had a market capitalization of AUD 315.9 million as of October 23, 2026. Its 52-week range was AUD 0.30 to AUD 1.07 on the same market-data snapshot, leaving execution, cash generation and the Agilex proceeds as the central valuation questions.

The further course of trading is shown by the continuously updated real-time quote of Healius stock.